On the issue of the new edition of the international classification of retinopathy of prematurity. Part 2

Abstract

Retinopathy of prematurity (ROP) is the leading cause of visual disability from early childhood. Foreign researchers and clinicians are focused on studying a new pharmacological method of treatment of active RN using anti-VEGF drugs, which was a reason that prompted updates in the International Classification of Retinopathy of Prematurity (ICROP) in 2021. The second part of the article presents new terms recommended by the Committee for the ICROP: “regression,” which refers to the involution and resolution of the disease, and “reactivation,” which denotes a recurrence of signs in the acute phase. Notably, the latest edition of the ICROP requires a deep understanding and accurate application by domestic specialists treating ROP. This contributes to the standardization of therapeutic and diagnostic processes, therefore, improving the quality of ROP treatment in Russia.

Keywords

retinopathy of prematurity / international classification

References

[1] Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, 3rd edition. Ophthalmology. 2021;128(10):51–68. doi.org/10.1016/j.ophtha.2021.05.031

[2] Chiang M.F., Quinn G.E., Fielder A.R., et al. International Classification of Retinopathy of Prematurity, 3rd edition // Ophthalmology. 2021. Vol. 128, N. 10. Р.51–68. doi: 10.1016/j.ophtha.2021.05.031

[3] Saidasheva EI. The new edition of the international classification of retinopathy of premature. Part 1. Russian Pediatric Ophthalmology. 2022;17(1):33–37. doi: 10.17816/rpoj100683

[4] Сайдашева Э.И. К вопросу о новой редакции международной классификации ретинопатии недоношенных. Часть 1 // Российская педиатрическая офтальмология. 2022. Т. 17, № 1. С. 33–37. doi: 10.17816/rpoj100683

[5] Saidasheva EI, Gorelik YV, Kovshov FV, et al. Experience in treating posterior aggressive retinopathy of prematurity by intravitreal administration of ranibizumab. Russian National Ophthalmological Forum. 2023;2:417–419. EDN: ZMRJYH

[6] Сайдашева Э.И., Горелик Ю.В., Ковшов Ф.В., и др. Опыт лечения задней агрессивной ретинопатии недоношенных путем интравитреального введения ранибизумаба // Российский Общенациональный Офтальмологический Форум. 2023. Т. 2. С. 417–419. EDN: ZMRJYH

[7] Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55(1):75–76. doi: 10.4103/0301-4738.29505

[8] Shah P.K., Narendran V., Tawansy K.A., et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematutity // Indian J Ophthalmol. 2007. Vol. 55, N. 1. Р. 75–76. doi: 10.4103/0301-4738.29505

[9] Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–615.

[10] Mintz-Hittner H.A., Kennedy K.A., Chuang A.Z. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity // N Engl J Med. 2011. Vol. 364, N. 7. Р. 603–615.

[11] Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551–1559. doi: 10.1016/S0140-6736(19)31344-3

[12] Stahl A., Lepore D., Fielder A., et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial // Lancet. 2019. Vol. 394, N. 10208. Р. 1551–1559. doi: 10.1016/S0140-6736(19)31344-3

[13] Stahl A, Sukgen EA, Wu WC, et al. FIREFLEYE Study Group. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA. 2022;328(4):348–359. doi: 10.1001/jama.2022.10564

[14] Stahl A., Sukgen E.A., Wu W.C., et al. FIREFLEYE Study Group. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial // JAMA. 2022. Vol. 328, N. 4. Р. 348–359. doi: 10.1001/jama.2022.10564

[15] Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32(3):434–457. doi: 10.1097/IAE.0B013E31822C290F

[16] Stewart M.W., Rosenfeld P.J., Penha F.M., et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) // Retina. 2012. Vol. 32, N. 3. Р. 434–457. doi: 10.1097/IAE.0B013E31822C290F

RIGHTS & PERMISSIONS

Eco-Vector